
Friday, March 19, 2021 9:12:19 AM
Over the entire industry, drug TRx are -1.6% w/w.
Vascepa
TRx 83,863; -3.5% w/w; -3.8% y/y
NRx 39,601; -3.2% w/w; -5.8% y/y
Ref 44,262; -3.9% w/w; -1.8% y/y
Generic Vascepa
TRx 9,531; +19.2% w/w; As % of total V: 10.2%
NRx 5,543; +18.9% w/w; As % of total V: 12.3%
Ref 3,989; +19.6% w/w; As % of total V: 8.3%
Lovaza (Generic & Brand)
TRx 62,953; -1.1% w/w; +1.6% y/y
NRx 32,143; -0.7% w/w; +6.4% y/y
Ref 30,811; -1.5% w/w; -2.9% y/y
Recent AMRN News
- Amarin Receives National Reimbursement for VAZKEPA® in Austria • GlobeNewswire Inc. • 02/25/2025 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025 • GlobeNewswire Inc. • 02/19/2025 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2025 09:45:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2025 09:45:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2025 09:45:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2025 10:00:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2025 10:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2025 10:00:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2024 09:15:07 PM
- Amarin Receives National Reimbursement for VAZKEPA® in Italy • GlobeNewswire Inc. • 12/16/2024 12:00:00 PM
- Amarin Appoints Peter Fishman Chief Financial Officer • GlobeNewswire Inc. • 12/13/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/22/2024 09:49:38 PM
- Investigators to Present New REDUCE-IT Subanalysis of VASCEPA®/VAZKEPA® (icosapent ethyl) in Patients With and Without Coronary Artery Disease History and Mechanistic Data on Eicosapentaenoic Acid (EPA) at the American Heart Association’s (AHA) Annual • GlobeNewswire Inc. • 11/11/2024 01:00:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2024 08:42:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/30/2024 08:10:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2024 08:10:08 PM
- Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 10/30/2024 08:05:00 PM
- Amarin Announces Two Upcoming Investor Events • GlobeNewswire Inc. • 10/01/2024 12:00:00 PM
- Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual Europe • GlobeNewswire Inc. • 09/09/2024 11:30:00 AM
- Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress • GlobeNewswire Inc. • 08/22/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/05/2024 09:30:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 11:05:34 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/31/2024 11:05:26 AM
FEATURED ImagineAR's FameDays Secures $10 Million Contract to Develop 25,000 Sq. Ft. Immersive Entertainment Center at a Niagara Falls Hotel in Canada • Feb 25, 2025 8:00 AM
Consumer Automotive Finance, Inc. Finalizes Agreement to Retire 246 Million Common Shares: Strategic Move Signals Robust Commitment to Shareholder Value Enhancement • CAFI • Feb 25, 2025 9:00 AM
VAYK To Offer Service Solution Capitalizing on $11.1 Billion Airbnb Revenue • VAYK • Feb 24, 2025 9:00 AM
ConnectM Announces $11.3M Q1 '25 Preliminary Revenue Guidance, a 100% YoY Surge • CNTM • Feb 24, 2025 9:00 AM
ConnectM Announces Q1 2025 Preliminary Revenue Guidance of $11.3M, Representing a 100% Year-Over-Year Surge • CNTM • Feb 21, 2025 7:17 AM
Consumer Automotive Finance Inc. (CAFI) Completes Final Steps with FINRA, Expects Name and Ticker Change to Fifty 1 Labs, Inc. (FITY) Within 30 Days • CAFI • Feb 20, 2025 9:00 AM